Search hospitals > Missouri > Chesterfield

Midwest Vision Research Foundation

Claim this profile
Chesterfield, Missouri 63017
Conducts research for Age-Related Macular Degeneration
Conducts research for Macular Degeneration
Conducts research for Diabetic Macular Edema
Conducts research for Macular Edema
Conducts research for Cystoid Macular Edema
17 reported clinical trials
1 medical researcher
Photo of Midwest Vision Research Foundation in ChesterfieldPhoto of Midwest Vision Research Foundation in ChesterfieldPhoto of Midwest Vision Research Foundation in Chesterfield

Summary

Midwest Vision Research Foundation is a medical facility located in Chesterfield, Missouri. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Diabetic Macular Edema, Macular Edema, Cystoid Macular Edema and other specialties. Midwest Vision Research Foundation is involved with conducting 17 clinical trials across 19 conditions. There are 1 research doctors associated with this hospital, such as Mujtaba Qazi, M.D..

Area of expertise

1Age-Related Macular Degeneration
Midwest Vision Research Foundation has run 9 trials for Age-Related Macular Degeneration.
2Macular Degeneration
Midwest Vision Research Foundation has run 6 trials for Macular Degeneration. Some of their research focus areas include:
Stage I
Stage II

Top PIs

Clinical Trials running at Midwest Vision Research Foundation

Age-Related Macular Degeneration
Macular Degeneration
Diabetic Macular Edema
Choroidal Neovascularization
Retinal Degeneration
Retinal Disease
None
Choroidal neovascularization
Wet AMD
Glaucoma
Image of trial facility.

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

PDS Implant with Ranibizumab

for Age-Related Macular Degeneration

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Recruiting2 awards Phase 33 criteria
Image of trial facility.

Zifibancimig

for Age-Related Macular Degeneration

This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Recruiting1 award Phase 1 & 26 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Midwest Vision Research Foundation?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security